Angioimmunoblastic T-cell lymphoma, or AITL, presents a difficult diagnosis to handle. This rare blood cancer affects T cells, a type of white blood cell responsible for fighting infection. When these cells grow abnormally and multiply out of control, they often build up in the lymph nodes and spread to other parts of the body. AITL is a subtype of non-Hodgkin lymphoma, and while it can occur at any age, it most commonly impacts older adults. The symptoms, which include swollen lymph nodes, fever, night sweats, skin rash, and unexplained weight loss, frequently resemble those of common infections or autoimmune conditions. This similarity often leads to delayed diagnosis, which requires a combination of lymph node biopsies, CT or PET scans, and sometimes a bone marrow biopsy.
Doctors use the Ann Arbor staging system to determine the severity of AITL. In stage I, the cancer is confined to a single lymph node region. Stage II means the disease has spread to nearby nodes but remains on one side of the diaphragm. These early stages are uncommon for patients. Stage III indicates involvement of lymph nodes on both sides of the diaphragm, while stage IV means the cancer has spread to organs such as the liver, bone marrow, or skin. Most people are diagnosed at one of these later stages.
Because AITL grows quickly, treatment usually starts soon after diagnosis. For early-stage disease, combination chemotherapy is standard, often paired with radiation to the affected areas. Advanced-stage disease is typically treated with the CHOP regimen, a combination of Cytoxan (cyclophosphamide), doxorubicin (hydroxydaunorubicin), Oncovin (vincristine sulfate), and prednisone. Another option, BV+CHP, incorporates Adcetris (brentuximab vedotin). Steroids may be added early to help manage immune-related symptoms like joint pain or rash.
Related: What Do Common Blood Tests Check For?
For those whose disease responds to chemotherapy, a stem cell transplant might follow to lower the risk of recurrence. This procedure can use the patient’s own stem cells or those from a donor. Targeted therapies addressing specific genetic changes are also used, especially in relapsed cases. Given the rarity of the condition and the constant development of new treatments, clinical trial participation is frequently encouraged. Patients facing significant toxicity from the smoke of wildfires may need to consult resources regarding toxicity management. Wildfire smoke exposure can aggravate respiratory systems, complicating the overall health picture for these individuals.
Chemotherapy side effects commonly include fatigue, nausea, hair loss, and lowered blood cell counts, which can increase infection risk. Steroids may cause mood changes, fluid retention, and sleep disruption. Stem cell transplant recipients face additional challenges, including a period of immune suppression and the potential for graft-versus-host disease. Recovery takes time, with patients often experiencing lingering fatigue, concentration difficulties, and heightened infection sensitivity in the months that follow. Emotional adjustments are equally important, as anxiety about recurrence and changes in daily life are real challenges that support groups and mental health professionals can help address. Regular follow-up appointments, imaging, and blood work remain essential long after treatment ends.
